Q1 2024 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2024-05-15 · accession 0001104659-24-061996
$7.97B
Reported value
87
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45337C102 | INCY | Incyte Corporation | $2.06B | 25.9% | 36,179,665 | Common | SOLE |
| 07725L102 | ONC | BeiGene, Ltd. | $1.65B | 20.7% | 10,568,897 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $792.6M | 9.94% | 42,864,612 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $526.0M | 6.60% | 1,969,798 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $277.2M | 3.48% | 6,398,365 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $243.3M | 3.05% | 7,549,249 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $241.0M | 3.02% | 5,995,928 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $124.7M | 1.56% | 27,525,640 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $123.1M | 1.54% | 4,942,823 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $106.5M | 1.34% | 5,840,059 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $98.5M | 1.24% | 1,515,318 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $91.1M | 1.14% | 17,310,490 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $78.1M | 0.98% | 7,413,834 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $78.0M | 0.98% | 9,545,336 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $76.6M | 0.96% | 3,731,695 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $68.9M | 0.86% | 4,865,819 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $68.5M | 0.86% | 2,713,205 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $68.5M | 0.86% | 1,466,547 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $67.7M | 0.85% | 6,443,398 | Common | SOLE |
| 15678U128 | CERE1EUR | Cerevel Therapeutics Holdings, Inc. | $67.6M | 0.85% | 1,600,000 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $59.5M | 0.75% | 151,215 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $57.1M | 0.72% | 3,882,125 | Common | SOLE |
| G5269C101 | — | Kiniksa Pharmaceuticals, Ltd. | $55.4M | 0.70% | 2,809,577 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals, Inc. | $51.4M | 0.65% | 10,126,176 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $49.7M | 0.62% | 1,680,517 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $49.5M | 0.62% | 5,434,399 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $48.0M | 0.60% | 10,123,824 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $46.6M | 0.58% | 1,062,123 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $45.5M | 0.57% | 3,368,443 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $42.8M | 0.54% | 993,679 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $39.5M | 0.49% | 4,088,322 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $36.8M | 0.46% | 19,477,339 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $34.7M | 0.43% | 4,916,095 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $33.5M | 0.42% | 1,552,478 | Common | SOLE |
| 09077A106 | BMEA | Biomea Fusion, Inc. | $31.5M | 0.40% | 2,108,949 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc. | $30.2M | 0.38% | 169,934 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $23.8M | 0.30% | 2,380,949 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc. | $23.2M | 0.29% | 456,015 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $22.5M | 0.28% | 1,691,530 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $22.1M | 0.28% | 2,784,792 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $17.0M | 0.21% | 10,787,022 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $13.7M | 0.17% | 425,009 | Common | SOLE |
| 901384107 | TSVT* | 2seventy bio, Inc. | $13.4M | 0.17% | 2,497,526 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $13.3M | 0.17% | 1,818,181 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $12.1M | 0.15% | 545,431 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $11.5M | 0.14% | 4,004,756 | Common | SOLE |
| 23306J101 | — | DBV Technologies S.A. | $10.9M | 0.14% | 14,614,264 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $10.4M | 0.13% | 247,644 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $9.6M | 0.12% | 1,160,117 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $9.3M | 0.12% | 343,000 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $9.0M | 0.11% | 2,177,826 | Common | SOLE |
| 640979100 | NMRA | Neumora Therapeutics, Inc. | $8.7M | 0.11% | 633,851 | Common | SOLE |
| 04746L104 | — | Athira Pharma, Inc. | $8.6M | 0.11% | 3,153,807 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $8.1M | 0.10% | 285,000 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines, Inc. | $8.0M | 0.10% | 131,533 | Common | SOLE |
| 78667J108 | SG7 | Sage Therapeutics, Inc. | $7.6M | 0.10% | 407,217 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $7.5M | 0.09% | 1,381,898 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine, Inc. | $7.2M | 0.09% | 1,028,466 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $6.7M | 0.08% | 1,662,120 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics, Inc. | $6.0M | 0.07% | 750,000 | Common | SOLE |
| 43906K100 | HOOKGBP | HOOKIPA Pharma Inc. | $5.8M | 0.07% | 8,128,151 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics, Inc. | $4.9M | 0.06% | 1,086,115 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals, Inc. | $4.8M | 0.06% | 190,476 | Common | SOLE |
| 87424L207 | TLIS | Talis Biomedical Corporation | $4.4M | 0.06% | 508,323 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $3.3M | 0.04% | 48,885 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics, Inc. | $3.3M | 0.04% | 797,460 | Common | SOLE |
| 02083G100 | NVLSEUR | Alpine Immune Sciences, Inc. | $3.2M | 0.04% | 81,578 | Common | SOLE |
| 35104E100 | FDMT | 4D Molecular Therapeutics, Inc. | $3.2M | 0.04% | 100,000 | Common | SOLE |
| 52187K200 | CYPH | Leap Therapeutics, Inc. | $3.1M | 0.04% | 1,172,175 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $3.1M | 0.04% | 1,557,630 | Common | SOLE |
| N62509109 | NAMS | NewAmsterdam Pharma Company N.V. | $2.3M | 0.03% | 96,827 | Common | SOLE |
| 918385204 | VTVT | vTv Therapeutics, Inc. | $2.3M | 0.03% | 97,314 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO, Inc. | $2.1M | 0.03% | 266,613 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics, Inc. | $2.0M | 0.03% | 2,076,400 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics, Inc. | $2.0M | 0.03% | 114,833 | Common | SOLE |
| 00449L102 | 698 | Achilles Therapeutics plc | $1.5M | 0.02% | 1,208,775 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio Co. | $1.5M | 0.02% | 371,219 | Common | SOLE |
| G63365103 | MURA | Mural Oncology plc | $1.1M | 0.01% | 222,503 | Common | SOLE |
| 717081103 | PFE | Pfizer Inc. | $971,250 | 0.01% | 35,000 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $800,681 | 0.01% | 199,671 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals, Inc. | $547,441 | 0.01% | 322,024 | Common | SOLE |
| 004890109 | ACRV | Acrivon Therapeutics, Inc. | $378,128 | 0.00% | 52,885 | Common | SOLE |
| 344174107 | FHTX | Foghorn Therapeutics Inc. | $302,131 | 0.00% | 45,027 | Common | SOLE |
| 12674W109 | CABA | Cabaletta Bio, Inc. | $227,427 | 0.00% | 13,331 | Common | SOLE |
| 46489V104 | ISREUR | Perspective Therapeutics, Inc. | $178,247 | 0.00% | 149,787 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences, Inc. | $173,955 | 0.00% | 10,607 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $25,167 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.